Cas No.: | 105219-56-5 |
Chemical Name: | Apafant |
Synonyms: | Apafant;3-[4-(2-Chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-2-yl]-1-(4-morpholinyl)-1-propanone;WEB 2086;[3H]-Web 2086;3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]-triazolo-[4,3-a][1,4]-diazepine-2-yl]-1-(4-morpholinyl)-1-propanone;3-[4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4-triazolo[4,3-a][1,4]-diazepine-2-yl]-1-(4-morpholinyl)]-1-propanone;4-(2-chlorophenyl)-9-methyl-2-[3-(4-morpholinyl)-3-propanone-1-yl]-6H-thieno-[3,2-f]-[1,2,4]triazolo[4,3-a][1,4]diazep;Apafanto;triazolodiazepine;WEB 2086BS |
SMILES: | O1CCN(C(CCC2=CC3C(C4=CC=CC=C4Cl)=NCC4=NN=C(C)N4C=3S2)=O)CC1 |
Formula: | C22H22ClN5O2S |
M.Wt: | 455.960381984711 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Apafant (WEB 2086), a potent platelet-activating factor (PAF) antagonist, inhibits PAF binding to human PAF receptors with a Ki of 9.9 nM[1]. |
Target: | Ki: 9.9 nM (Platelet-activating factor)[1] |
References: | [1]. Kato M, et al. Apafant, a potent platelet-activating factor antagonist, blocks eosinophil activation and is effective in the chronic phase of experimental allergic conjunctivitis in guinea pigs. J Pharmacol Sci. 2004 Aug;95(4):435-42. |